Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 228 participants.
Also called NCT04980027
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 228 participants
- Sponsor
- Registry
-
NCT04980027
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- India
- Registry status
- Completed
Technical summary
Registry record NCT04980027. Allocation not applicable; no masking; primary purpose treatment. Start 2021-06-07 (actual); primary completion 2022-12-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs
- Acronym
- SAFEGUARD
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine (U300)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct04980027- Content hash
8f78cffd62d446506ce4a910b15d67ad4596ccda156ab30db586ac4158cd153d